Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025
Builds On Initial 2018 Agreement While Aligning With Fresenius Kabi’s 2026 Vision
European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.
You may also be interested in...
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
Fresenius Kabi continues to feel confident “that we’re going to be pretty much first to market” for its Tyenne proposed biosimilar to Actemra in the US.
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.